Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q3 2025 value amounting to -$1.4 million.

  • Vanda Pharmaceuticals' Gains from Investment Securities fell 18778.47% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.2 million, marking a year-over-year decrease of 12912.66%. This contributed to the annual value of -$2.6 million for FY2024, which is 2357.41% up from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Gains from Investment Securities is -$1.4 million, which was down 18778.47% from -$1.0 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Gains from Investment Securities peaked at -$295000.0 during Q1 2021, and registered a low of -$1.9 million during Q1 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' median Gains from Investment Securities value was -$641000.0 (recorded in 2024), while the average stood at -$762789.5.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 4795.26% in 2024, then tumbled by 18907.96% in 2025.
  • Vanda Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$506000.0 in 2021, then tumbled by 66.8% to -$844000.0 in 2022, then rose by 23.34% to -$647000.0 in 2023, then tumbled by 49.92% to -$970000.0 in 2024, then plummeted by 43.3% to -$1.4 million in 2025.
  • Its last three reported values are -$1.4 million in Q3 2025, -$1.0 million for Q2 2025, and -$1.9 million during Q1 2025.